Research on Digestive and Liver Diseases in FP7

Maria José Vidal-Ragout, MD, PhDHead of Unit, Medical Research

Directorate-General for Research & InnovationEuropean Commission

Content

1.EU digestive and liver disease's research: How does it work?

2.What has been addressed?

3.The future: Horizon 2020

• Provide evidence-based solutions for clinical challenges and develop preventive approaches

• Address common risk factors (e.g. obesity, alcohol, infection, lifestyle, etc.) and identify vulnerable populations

• Foster improved diagnosis, early detection and stratified therapies

• Provide proof-of-concept for the establishment of integrated care approaches

Strategic objectives for research on digestive and liver diseases

How?

EU research

on digestive and liver diseases

Collaborative

Research

Public-Private

Partnerships

IMI

CapacityBuilding

infrastructures

LegislationDirectives, Regulations

Bottom-upresearch

ERC, People

Internationalco-

operationGACD

MS Coordinatio

nERA-NET

JPIs

EU digestive and liver diseases 'researchSchemes and funds(in Million Euro)

EU digestive and liverdiseases’ researchWhat’s being funded

€ 382,8 million on research on digestive and liver diseases (2007-2012)

development of new therapies

Large-scale genetic studies

mechanistic and animal model studies

computer simulation of digestive system

Stem cells research and artificial liver

mathematical modelling of cell proliferation and tissue organization in tumours

molecular analysis of hepatitis virus

development of imaging tools

IT applications for patient support

comorbidities

training and mobility programmes

DNA methylation kits for clinical analyses of liver and colon cancers

The Use of Methylated DNA Immunoprecipitation (MeDIP) in Cancer for better Clinical Management

Altered epigenetic status:prognostic markers for colon cancer patients

EU health research delivers results to patients

Role of inflammation in tumour initiationand progression

Prognostic markers for GIST patients

EU health research concentrates scarce

resources

http://inflacare.imbb.forth.gr/

EU health research fosters evidence-based best clinical care

http://www.ibdase.org

7 academic partners, 2 SMEs 5 years € 2.9 million Start date: March 2008

EU health research contributes to tailor treatment to individual patients

From ethiopatogenetic insight into innovative therapy

Public Private Partnerships: –the Innovative Medicines Initiative

MIP-DILI: Mechanism-Based Integrated Systems for the Prediction of Drug-Induced Liver Injury

http://www.mip-dili.eu

10 academic partners, 6 SMEs, 11EFPIA partners

5 years € 32.4 million Start date: February 2012

Develop models that take into account the natural differences between patients

Evidence-based evaluation of both currently available and new laboratory test systems

Challenges in research on digestive and liver diseases

• Better prevention

• Novel biomarkers for disease

• Investigator-driven CTs

• Stratified patient populations and targeted therapies

• Innovative technology and devices

• Increased incidence of lifestyle associated diseases, e.g. alcohol consumption

• Co-morbidity, e.g. ageing, obesity, diabetes

• Patient-reported outcomes© pixologic, #43498499, 2012. Source : www.fotolia.com

Digestive and liver diseases

Cancer

Towards joint programming in research Working together to tackle common challenges more effectively, EU COM (2008) 468

Low coordination, high fragmentation, invest less than in the US

Improvements still need to be made…

EU research budget represents only ~ 5% of research expenditure in MS

• Increasing pressure on European healthcare systems

• Raising costs

• Over-utilisation of care, differences in outcomes, rapid expansion and shortening life cycles of technologies and insufficient comparative assessment of current practices and approaches

To address significant challenges…

…and benefit from opportunities

• Stratified and subsequently personalised medicine can deliver cost savings and better outcomes for patients

• But the building blocks are many and linked, requiring clinical trials, a better understanding of disease and comorbidity, and efforts to translate results to the clinic

Horizon 2020: The next Framework Programme for research and innovation

Europe needs cutting edge research and innovationEssential to ensure competitiveness, growth and jobsVital to tackle pressing societal challenges 3% of GDP invested in R&D: headline target of Europe 2020

Proposed budget: €80bn, a 46% increase compared to FP7

Horizon 2020 novelties• Simplification:

• Simpler programme architecture, a single set of rules

• Easy to use cost reimbursement model: one project - one funding rate

• Less paperwork in preparing proposals• Reduce time to grant by 100 days

• Inclusive approach:• More support for innovation and activities

close to the market• Strong focus on creating business

opportunities • New SBIR-like scheme dedicated to SMEs

• Renewed successful partnerships: • EDCTP• IMI

© Fotolia.com

Horizon 2020: Health, Demographic Change and Wellbeing Challenge Proposal: ~ €8.5bn

• Understanding the determinants of health (including environmental and climate related factors), improving health promotion and disease prevention;

• Developing effective screening programmes and improving the assessment of disease susceptibility

• Improving surveillance and preparedness

• Understanding disease• Developing better preventive vaccines

• Improving diagnosis• Using in-silico medicine for improving

disease management and prediction

• Treating disease• Transferring knowledge to clinical practice

and scalable innovation actions

• Better use of health data

• Improving scientific tools and methods to support policy making and regulatory needs

• Active ageing, independent and assisted living

• Individual empowerment for self-management of health

• Promoting integrated care

• Optimising the efficiency and effectiveness of healthcare systems and reducing inequalities through evidence based decision making and dissemination of best practice, and innovative technologies and approaches.

Horizon 2020: Health Challenge:Some of the key features

• Adapting to an ageing population

• Pursuing the path to more personalised medicine

• Translational research (clinical trials)

• Harnessing and encouraging private sector capability

• Coordinating national efforts

• Reducing costs (comparative effectiveness research)

• Expanding global cooperation

Thank you!

Role of inflammation in tumour initiationand progression

Prognostic marker for GIST patients 5H2TB inhibitor reduces liver fibrosis

EU health research delivers results to patients

http://inflacare.imbb.forth.gr/